Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

Journal of Clinical Oncology

Volumn 27, Issue 25, 2009, Pages 4047-4054

  McNeel, Douglas G ^a   Dunphy, Edward J ^a   Davies, James G ^a   Frye, Thomas P ^a   Johnson, Laura E ^a   Staab, Mary Jane ^a   Horvath, Dorothea L ^a   Straus, Jane ^a   Alberti, Dona ^a   Marnocha, Rebecca ^a   Liu, Glenn ^a   Eickhoff, Jens C ^a   Wilding, George ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; AMYLASE; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; PLASMID DNA; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; PROTEIN TYROSINE PHOSPHATASE;

ADULT; AGED; AMYLASE BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; BACKACHE; CANCER PATIENT; CANCER STAGING; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DNA IMMUNIZATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; HEADACHE; HUMAN; HUMAN CELL; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; LYMPHOCYTE PROLIFERATION; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SIDE EFFECT; TACHYCARDIA; TREATMENT RESPONSE; ADENOCARCINOMA; BLOOD; ENZYMOLOGY; IMMUNOLOGY; IMMUNOTHERAPY; INTRADERMAL DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRADERMAL; INTERFERON-GAMMA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; TIME FACTORS; TREATMENT OUTCOME; VACCINES, DNA;

EID: 70249126960     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.9968     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
2. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
3. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005
4. Slovin SF, Wilton AS, Heller G, et al: Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 11:8669-8673, 2005
5. Lee AK, Levy LB, Cheung R, et al: Prostatespecific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63:456-462, 2005
6. Freedland SJ, Humphreys EB, Mangold LA, et al: Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25:1765-1771, 2007
7. Kipp RT, McNeel DG: Immunotherapy for prostate cancer: Recent progress in clinical trials. Clin Adv Hematol Oncol 5:465-74:477-479, 2007
8. McNeel DG: Prostate cancer immunotherapy. Curr Opin Urol 17:175-181, 2007
9. Gutman AB, Gutman EB: An acid phosphatase in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 17: 473-479, 1938
10. Terracio L, Rule A, Salvato J, et al: Immuno-fluorescent localization of an androgen-dependent isoenzyme of prostatic acid phosphatase in rat ventral prostate. Anat Rec 213:131-139, 1985
11. Fong L, Ruegg CL, Brockstedt D, et al: Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization; implications for immunotherapy of prostate cancer. J Immunol 159:3113-3117, 1997
12. Johnson LE, Frye TP, Chinnasamy N, et al: Plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) is effective in eliciting autologous antigen-specific CD8+ T cells. Canc Immunol Immunoth 56:885-895, 2007
13. Small EJ, Schellhammer PF, Higano CS, et al: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089-3094, 2006
14. Cavallo F, Signorelli P, Giovarelli M, et al: Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 89:1049-1058, 1997
15. Hawkins WG, Gold JS, Blachere NE, et al: Xenogeneic DNA immunization in melanoma models for minimal residual disease. J Surg Res 102: 137-143, 2002
16. Johnson LE, Frye TP, Arnot AR, et al: Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine 24:293-303, 2006
17. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999
18. Whiteside TL: Immunologic monitoring of clinical trials in patients with cancer: Technology versus common sense. Immunol Invest 29:149-162, 2000
19. Kreher CR, Dittrich MT, Guerkov R, et al: CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods 278:79-93, 2003
20. McNeel DG, Nguyen LD, Ellis WJ, et al: Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate 47:222-229, 2001
21. Pavlenko M, Roos AK, Lundqvist A, et al: A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91:688-694, 2004
22. Wolchok JD, Gregor PD, Nordquist LT, et al: DNA vaccines: An active immunization strategy for prostate cancer. Semin Oncol 30:659-666, 2003